CORAL GABLES, Fla. — November 4, 2025 — Leads & Copy — Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced the pricing of its underwritten offering of 40,142,000 shares of common stock and pre-funded warrants to purchase up to 5,315,000 shares. The shares are priced at $2.20 each, and pre-funded warrants at $2.199 each.
The offering is expected to generate approximately $100 million in gross proceeds for Relmada before deducting underwriting discounts, commissions, and other expenses. The offering is set to close on November 5, 2025, pending customary closing conditions.
Investors include Janus Henderson Investors, Ferring Ventures SA, Squadron Capital Management, Marshall Wace, Spruce Street Capital, OrbiMed, Columbia Threadneedle Investments and Driehaus Capital Management.
Jefferies and Leerink Partners are joint book-running managers; Mizuho is a book-runner. Relmada plans to use the net proceeds for working capital and general corporate purposes, including clinical studies, regulatory compliance, product development, acquisitions, and licensing activities.
The securities were offered under a shelf registration statement declared effective by the SEC on September 12, 2024. Copies of the final prospectus supplement and base prospectus can be obtained from Jefferies LLC, Leerink Partners LLC, or Mizuho Securities USA LLC.
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Corporate Communications
media@relmada.com
Source: Relmada Therapeutics
